| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O |
| P698 | PubMed publication ID | 10861435 |
| P50 | author | Janet Daling | Q20807295 |
| Noel S. Weiss | Q88546264 | ||
| P2093 | author name string | J L Stanford | |
| C I Li | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hormone Replacement Therapy | Q108667313 |
| breast carcinoma | Q18555947 | ||
| P304 | page(s) | 2570-2577 | |
| P577 | publication date | 2000-06-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women | |
| P478 | volume | 88 |
| Q36623700 | A population-based cohort study of HRT use and breast cancer in southern Sweden |
| Q36468547 | Alcohol and breast cancer tumor subtypes in a Spanish Cohort |
| Q34132812 | Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study |
| Q36615906 | An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk |
| Q95785622 | Author reply |
| Q27012792 | Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status |
| Q35134608 | Breast cancer and post-menopausal hormone therapy |
| Q34580677 | Breast cancer prevention through the eyes of a survivor |
| Q57648881 | Changing incidence of lobular carcinoma in situ of the breast |
| Q79325897 | Clarifying breast cancer risks associated with menopausal hormone therapy |
| Q36615540 | Clinical characteristics of different histologic types of breast cancer |
| Q79092117 | Current Controversies: Hormone Replacement Therapy and Breast Cancer |
| Q42964146 | Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin |
| Q34358592 | Different gene expression patterns in invasive lobular and ductal carcinomas of the breast |
| Q38029548 | Effects of omega-3 fatty acids on progestin stimulation of invasive properties in breast cancer |
| Q36611606 | Established breast cancer risk factors by clinically important tumour characteristics |
| Q28572162 | Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats |
| Q36529006 | Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features |
| Q36216717 | Factors that influence the incidence of breast cancer in Arica, Chile (Review). |
| Q34572280 | Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis |
| Q74662523 | Hormone replacement therapy and breast cancer, revisited |
| Q47436578 | Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study |
| Q46630833 | Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma |
| Q46302786 | Increase in breast cancer incidence in middle-aged women during the 1990s |
| Q73878460 | Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy |
| Q34179808 | Late age at first full term birth is strongly associated with lobular breast cancer |
| Q35170028 | Lobular breast cancer: incidence and genetic and non-genetic risk factors |
| Q34255801 | Membrane progesterone receptors (mPRs) mediate progestin induced antimorbidity in breast cancer cells and are expressed in human breast tumors |
| Q37370478 | Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort |
| Q37203133 | Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? |
| Q34480625 | Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study |
| Q34341910 | Menopause, hormone replacement therapy and cancer |
| Q35588813 | Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial |
| Q33579730 | Perspectives of breast cancer etiology: synergistic interaction between smoking and exogenous hormone use. |
| Q43864580 | Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer |
| Q35948658 | Postmenopausal hormone therapy and breast cancer: a clinician's message for patients |
| Q36695646 | Primary systemic chemotherapy of invasive lobular carcinoma of the breast |
| Q36844266 | Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors |
| Q24800282 | Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies |
| Q38761522 | Progestin-mediated activation of MAPK and AKT in nuclear progesterone receptor negative breast epithelial cells: The role of membrane progesterone receptors |
| Q37496576 | Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer |
| Q81803964 | Rapid immunohistochemistry enhances the intraoperative diagnosis of sentinel lymph node metastases in invasive lobular breast carcinoma |
| Q43753113 | Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma |
| Q79103489 | Reproductive and anthropometric factors in relation to the risk of lobular and ductal breast carcinoma among women 65–79 years of age |
| Q36615101 | Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology |
| Q33903091 | Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population |
| Q56030089 | Sex hormones and related compounds, including hormonal contraceptives |
| Q41169486 | Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population |
| Q52727420 | The Proliferative Response to p27 Down-Regulation in Estrogen Plus Progestin Hormonal Therapy is Lost in Breast Tumors. |
| Q34555256 | The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer |
| Q35089975 | The menopause, hormone replacement therapy and breast cancer |
| Q42730607 | The relationship between hormone therapy use at the time of diagnosis of breast cancer and tumor characteristics |
| Q78384483 | Tumor characteristics predictive of sentinel node metastases in 105 consecutive patients with invasive lobular carcinoma |
| Q36593545 | Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer |
| Q33823771 | Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age |
| Q50490813 | Validation of axillary sentinel lymph node detection in the staging of early lobular invasive breast carcinoma: a prospective study. |
Search more.